Focused measurement of symptoms that matter to patients
The Lung Cancer Symptom Scale (LCSS) is a disease- and site-specific instrument designed for clinical trials and clinical practice. It focuses on symptoms and the physical and functional dimensions of quality of life most likely to be affected by lung cancer and its treatment.
LCSS
A concise measure for people with lung cancer, consisting of a patient scale and an optional counterpart observer scale for health professionals.
LCSS-Meso
A mesothelioma-specific adaptation that retains the symptom-focused approach of the LCSS while reflecting the experience of patients with malignant pleural mesothelioma.
Simple for patients. Meaningful for research.
The LCSS uses visual analogue response scales to capture patient-reported symptoms and quality of life. Patients indicate their response by marking a position along each scale, providing a simple visual method for recording symptom severity and impact.
Developed and psychometrically validated
The LCSS has been evaluated through multicenter reliability and validity testing and subsequent research examining measurement properties, clinical applications, longitudinal assessment and electronic administration. The LCSS-Meso has also undergone dedicated development and psychometric evaluation for malignant pleural mesothelioma.
Clinical meaningfulness
Research with the LCSS has examined not only statistical significance, but also whether changes in patient scores represent clinically meaningful differences. Comparisons with observer ratings and performance status have contributed to the evidence supporting responsiveness to changes in patient condition.
Research literature
The evidence base includes foundational development and validation studies, psychometric and methodologic research, clinical studies, mesothelioma research and electronic patient-reported outcome assessment.
Explore Publications & Research →The origins of the LCSS
Originally developed by Richard Gralla at Memorial Sloan Kettering Cancer Center and first published in 1985, the LCSS was created to provide a practical, patient-centered method for assessing symptoms and quality of life in people with lung cancer. Subsequent development, testing and validation led to the LCSS Patient and Observer Scales.
The LCSS Patient and Observer Scales were authored by Patricia J. Hollen, PhD, RN, FAAN; Richard J. Gralla, MD, FACP, FMASCC; and Mark G. Kris, MD.
Over the following decades, the LCSS underwent expanded reliability and validity testing, translation and cultural validation, electronic adaptation and use in clinical research internationally. The LCSS-Meso was subsequently developed for malignant pleural mesothelioma.
A collaborative effort
The development and validation of the LCSS reflects the contributions of patients, medical oncologists, oncology nurses, statisticians, researchers and industry collaborators across multiple institutions. Their participation in development, psychometric testing, translation and continued evaluation helped establish the LCSS as a widely used measure in lung cancer research.